Our team of R&D leaders from human biotech and animal health is building the premier biotechnology platform for protein-based therapeutics in animal health.
Location: United States, Massachusetts, Boston
Total raised: $101M
Investors 4
| Date | Name | Website |
| - | Anterra Ca... | anterracap... |
| 10.06.2023 | F-Prime Ca... | fprimecapi... |
| 28.05.2022 | Eight Road... | eightroads... |
| 09.08.2022 | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.05.2022 | Series B | $60.5M | GlobeLab |
| 01.10.2020 | Series A | $25.5M | - |
| 24.02.2020 | Series A | $15M | - |
Mentions in press and media 20
| Date | Title | Description |
| 18.06.2026 | The food system needs a rewiring, not a reinvention, Anterra Capital says after $100m raise | “The key in our space is not to focus on creating new categories but focus on the system itself and rewire it,” Anterra Capital founding partner Maarten Goossens said this week as his firm announced a $100 million first close of its Fund II... |
| 16.06.2026 | Anterra Capital Fuels Agri-Food Revolution with $100M AI, Biology Fund | Anterra Capital announced a $100 million first close for its third fund. This significant capital influx targets artificial intelligence and biological innovation across the $10 trillion global food and agriculture sector. The firm, managin... |
| 15.06.2026 | Anterra Capital: $100 Million First Close Of Fund III Targets AI And Biology Opportunities In Food And Agriculture | Anterra Capital announced the first close of its third fund at $100 million, with a target size of $200 million, as the specialist venture firm looks to capitalize on emerging opportunities created by artificial intelligence and biological ... |
| 27.08.2025 | Harbour BioMed Reports 2025 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ... |
| 03.02.2025 | Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery | CAMBRIDGE, Mass., Feb. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced today that it has entered into a strategic collaboration with ... |
| 01.04.2024 | Old Dogs Can Inspire New Business Models | 13 Shares Email Facebook Twitter LinkedIn People with puppies are tired. People with senior dogs are broke. That, in oversimplified terms, is a pretty consistent anecdotal finding among pet owners. As furry friends age, their people face th... |
| 10.05.2022 | Invetx raises $60.5 million to make long-lasting antibody therapies for cats and dogs | - |
| 10.05.2022 | Our investment in Invetx | Invetx is positioned to bring portfolio of novel antibody product candidates through development to market approval. The investment was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation... |
| 10.05.2022 | Invetx Raises $60.5M in Series B Funding | Invetx, a Boston, MA-based pioneer in protein-based therapeutics for animal health, raised $60.5m in Series B financing. The round was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation ... |
| 10.05.2022 | Invetx announces oversubscribed Series B financing of $60.5 million to advance portfolio of best-in-class veterinary biotherapeutics | From Invetx.com |
Show more